Angioid Streak-Related Choroidal Neovascularization Treated by Intravitreal Ranibizumab

Vadalà, Maria; Pece, Alfredo; Cipolla, S.; Monteleone, Carla; Ricci, Federico; Boscia, Francesco; Cillino, Salvatore

doi:10.1097/iae.0b013e3181cafc75

Cited by 22 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since PXE is a rare disorder, much of the experience for the treatment of AS-associated CNV emerges from causes other than PXE. Published literature on anti-VEGF treatment for CNV secondary to AS, mainly case series or studies with either a small sample size or short follow-up, report VA gain or stabilization in 85–93% of the study population [ 25 – 28 ]. Tilleul et al reported long-term effectiveness of ranibizumab in the largest series (35 eyes of 27 patients) with AS-associated CNV of which 40.7% was due to PXE [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

“…Anti-vascular endothelial growth factor (VEGF) therapy has been used successfully for the treatment of CNV associated with age-related macular degeneration (AMD) [ 19 , 20 ]. Likewise, treatment with anti-VEGF agents such as bevacizumab (Avastin®; Genentech/Roche) [ 21 ], and ranibizumab (Lucentis®; Genentech, South San Francisco, CA, USA; and Novartis Pharma AG, Basel, Switzerland) [ 22 ] has shown promise in CNV secondary to AS in several small studies with a short follow-up duration [ 23 – 28 ]; a recently published long-term retrospective study reinforces these short-term outcomes [ 29 ]. However, all these studies are in patients with AS-associated CNV in causes other than PXE.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Mimoun¹,

Ebran

Grenet

et al. 2017

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

PurposeTo evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) in a real-world setting.MethodsA descriptive, observational, multicenter study in a retrospective and prospective cohort was conducted in France that included patients who had received at least one injection of ranibizumab 0.5 mg during the period October 2011 to October 2014, for CNV secondary to PXE. Eligible patients were identified by review of medical records or during routine consultations. The main objectives were to describe patient characteristics, assess changes in best-corrected visual acuity [VA, Early Treatment Diabetic Retinopathy Study (ETDRS) letters] over time, the number and reasons for ranibizumab treatment and overall safety.ResultsOf the 72 enrolled patients (98 eyes) from 23 centers, 39 (54.2%) were male and mean [±standard deviation (SD)] age was 59.6 (±8.3) years. The mean VA was 64.6 letters at the first ranibizumab injection, which was maintained at the 1-year follow-up (64.7 letters). Thereafter, the mean VA was stable until the 4-year follow-up. At 4 years, the proportion of eyes with VA gain of ≥15 letters was 3/19 (15.8%) and stable VA (change between −15 and +15 letters) was 10/19 (52.6%). Mean (±SD) annual number of ranibizumab injections was 4.1 (±4.0), lower in the second versus first year. The most common reason for ranibizumab treatment was progression of neovascular activity (42.9%). No deaths or new safety findings were reported.ConclusionsIn patients with CNV secondary to PXE, ranibizumab 0.5 mg resulted in stable VA over 4 years with a limited number of injections. Safety findings were consistent with the established safety profile of ranibizumab.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Mimoun¹,

Ebran

Grenet

et al. 2017

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…There was also a significant reduction in mean OCT macular thickness at last follow-up. 20 Finger et al 21 published a 12-month prospective study of seven eyes and demonstrated a significant improvement in visual acuity from baseline with a reduction in mean CRT and leakage from active CNVs.…”

Section: Discussionmentioning

confidence: 99%

“…However, most of these studies are limited to single case reports, small numbers of patients or have limited/short follow-up. [16][17][18][19][20][21][22] We report a retrospective case series that assesses the medium to long-term efficacy and safety of intravitreal ranibizumab in patients with CNV secondary to AS.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Shah

Amoaku

2012

Eye

View full text Add to dashboard Cite

Aims To assess the medium to long-term efficacy and safety of intravitreal ranibizumab for the treatment of choroidal neovascularisation (CNV) secondary to angioid streaks (AS). Methods A total of 12 eyes of nine patients treated with intravitreal ranibizumab (0.5 mg in 0.05 ml) for CNV secondary to AS were retrospectively identified. Efficacy of treatment was determined by changes in best-corrected LogMAR visual acuity (BCVA) and optical coherence tomography. Changes with respect to baseline BCVA were defined as improved or reduced with a gain or loss of more than 10 letters, respectively, or stable if remaining within 10 letters. Results Over a mean follow-up of 21.75 months (range: 1-54), patients received mean 5.75 (range: 2-15) intravitreal ranibizumab injections per affected eye. BCVA improved in three eyes (25%), stabilised in eight eyes (66.67%), and deteriorated in one eye (8.33%). There was no significant change in central retinal thickness (CRT) over the follow-up period (P ¼ 0.1072). No drug-related systemic side effects were recorded. Conclusion The long-term treatment of CNV secondary to AS with intravitreal ranibizumab showed a stabilisation in CRT and an improvement or stabilisation of BCVA. The absence of systemic side effects was reassuring. Further long-term prospective studies are required to validate these findings.

show abstract

“…Several studies have shown that IVR is highly effective in patients with CNV secondary to angioid streaks. [32][33][34][35] Ladas et al 34 recently reported encouraging results in the treatment of angioid streaks with IVR. However, before our study, no studies have been conducted to ascertain the effect of combination treatment with rfPDT and IVR injection for CNV attributable to angioid streaks.…”

Section: Discussionmentioning

confidence: 96%

Combination Treatment With Intravitreal Injection of Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization Secondary to Angioid Streaks

Artunay

Yüzbaşıoğlu²,

Rasier³

et al. 2011

Retina

View full text Add to dashboard Cite

The preliminary results of this prospective study indicate that combination treatment with intravitreal ranibizumab injection and reduced fluence photodynamic therapy for choroidal neovascularization associated with angioid streaks seems to be effective in reducing or eliminating retinal edema, regression of neovascularization, and improving or stabilizing visual acuity without any complications. Large controlled studies are needed to evaluate the long-term effects of this combination regimen.

show abstract

Angioid Streak-Related Choroidal Neovascularization Treated by Intravitreal Ranibizumab

Abstract: Ranibizumab can be considered as an effective therapy in angioid streak-related neovascularization, even if in an off-label setting.

Cited by 22 publications

References 22 publications

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

Combination Treatment With Intravitreal Injection of Ranibizumab and Reduced Fluence Photodynamic Therapy for Choroidal Neovascularization Secondary to Angioid Streaks

Contact Info

Product

Resources

About